On June 10, 2011, Accuray completed the acquisition of TomoTherapy. As a total result, the first quarter financial data presented reflect the consolidation of both TomoTherapy and Accuray.5 million and non-GAAP total revenue of $95.7 million. By comparison, september 30 for the quarter ended, 2010 the sum of the revenue reported by Accuray and TomoTherapy as distinct companies if combined totaled $81.7 million. Income in the first one fourth of fiscal 2012 was driven by strong TomoTherapy System installations. The consolidated GAAP gross profit %age for the first quarter of fiscal 2012 was 31.7 % for products and 13.9 % for services.4 % for items and 12.1 % for services.Median overall survival was 11.3 months in the control group, 12.4 months in the complete Imprime PGG group. Serum ABA levels might be a predictive biomarker for Imprime PGG activity. Further analysis to characterize the predictive significance of the biomarker is certainly ongoing. Establishment of a predictive biomarker for Imprime PGG will enable the enrichment of upcoming clinical trials and, ultimately, provide oncologists with extra equipment for evaluating treatment options for their patients, stated Dan Conners, president of Biothera's Pharmaceutical Group.